CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.013
https://www.valueinhealthjournal.com/article/S1098-3015(18)33313-8/fulltext
Title :
CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33313-8&doi=10.1016/j.jval.2018.09.013
First page :
Section Title :
Open access? :
No
Section Order :
578